{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:18:32Z","timestamp":1792531112167,"version":"4.5.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL062996"],"award-info":[{"award-number":["R01 HL062996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES031087"],"award-info":[{"award-number":["R01 ES031087"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Rosacea is a chronic inflammatory skin condition associated with a significant health and economic burden from costs and loss of productivity due to seeking medical treatment. The disease encompasses multiple phenotypic manifestations involving a complex and multi-variate pathogenesis. Although the pathophysiology of rosacea is not completely understood, ongoing research is continually elucidating its mechanisms. In this review, current concepts of rosacea pathogenesis will be addressed which involve skin barrier and permeability dysfunction, the innate and adaptive immune systems, and the neurovascular system. More specifically, the cathelicidin pathway, transient potential receptor channels, mast cells, and the NLRP3 inflammasome pathway are various targets of current pharmacologic regimens. Future therapies may seek different mechanisms to act on current treatment targets, like the potential use of JAK\/STAT inhibitors in ameliorating skin barrier dysfunction or TLR antagonists in alleviating cathelicidin mediated inflammation. Other potential treatments aim for entirely different molecular targets such as microvesicle particle mediated local and systemic inflammation. Ultimately rosacea is associated with a significant health and economic burden which warrants deeper research into its pathogenesis and resultant new treatment discovery.<\/jats:p>","DOI":"10.3389\/fmed.2023.1292722","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:28:50Z","timestamp":1702423730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Rosacea pathogenesis and therapeutics: current treatments and a look at future targets"],"prefix":"10.3389","volume":"10","author":[{"given":"Garrett W.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1468-3083.2009.03472.x","article-title":"Risk factors associated with rosacea","volume":"24","author":"Abram","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/ijd.15989","article-title":"Epidemiology of rosacea in a population-based study of 161,269 German employees","volume":"61","author":"Hilbring","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jaad.2017.09.016","article-title":"Comorbidities in rosacea: a systematic review and update","volume":"78","author":"Haber","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jaad.2016.12.043","article-title":"The burden of skin disease in the United States","volume":"76","author":"Lim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"13030\/qt1mv9r0ss","DOI":"10.5070\/D32010024262","article-title":"Rosacea in skin of color: not a rare diagnosis","volume":"20","author":"Al-Dabagh","year":"2014","journal-title":"Dermatol Online J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","article-title":"Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience","volume":"80","author":"Alexis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4103\/ijdvl.IJDVL_769_19","article-title":"Rosacea in skin of color: a comprehensive review","volume":"86","author":"Sarkar","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.36849\/JDD.6062","article-title":"Update on facial erythema in Rosacea","volume":"20","author":"Gallo","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40257-021-00595-7","article-title":"Rosacea: new concepts in classification and treatment","volume":"22","author":"van Zuuren","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/jid.2010.351","article-title":"TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes","volume":"131","author":"Yamasaki","year":"2011","journal-title":"J Invest Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/jid.2015.141","article-title":"Molecular and morphological characterization of inflammatory infiltrate in Rosacea reveals activation of Th1\/Th17 pathways","volume":"135","author":"Buhl","year":"2015","journal-title":"J Investig Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society expert committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/sj.cr.7310029","article-title":"STAT3 in immune responses and inflammatory bowel diseases","volume":"16","author":"Fu","year":"2006","journal-title":"Cell Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/JIR.S356551","article-title":"Multi-transcriptomic analysis and experimental validation implicate a central role of STAT3 in skin barrier dysfunction induced aggravation of Rosacea","volume":"15","author":"Wang","year":"2022","journal-title":"J Inflamm Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e23363","DOI":"10.1002\/jcla.23363","article-title":"Rosacea is associated with conjoined interactions between physical barrier of the skin and microorganisms: a pilot study","volume":"34","author":"Yuan","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"SF3595563","DOI":"10.36849\/JDD.m0922","article-title":"Supplement article: skin barrier deficiency in Rosacea: an algorithm integrating OTC skincare products into treatment regimens","volume":"21","author":"Baldwin","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.jid.2020.02.025","article-title":"Rosacea is characterized by a profoundly diminished skin barrier","volume":"140","author":"Medgyesi","year":"2020","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3389\/fimmu.2020.01137","article-title":"Cathelicidins modulate TLR-activation and inflammation","volume":"11","author":"Scheenstra","year":"2020","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3390\/cimb45040177","article-title":"Long-term administration of LL-37 can induce irreversible Rosacea-like lesion","volume":"45","author":"Zhang","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ddg.13139","article-title":"Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy","volume":"14","author":"Reinholz","year":"2016","journal-title":"J Deutsc Dermatol Ges"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1096\/fj.06-6075com","article-title":"Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin","volume":"20","author":"Yamasaki","year":"2006","journal-title":"FASEB J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jid.2021.02.745","article-title":"Antimicrobial peptide LL-37 drives Rosacea-like skin inflammation in an NLRP3-dependent manner","volume":"141","author":"Yoon","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.jid.2021.04.024","article-title":"Cathelicidin LL-37 ignites primed NLRP3 Inflammasomes in Rosacea","volume":"141","author":"Croitoru","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/5584_2017_59","article-title":"The P2X7 receptor","volume":"1051","author":"Sluyter","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jdermsci.2014.09.002","article-title":"Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: possible implications for rosacea","volume":"76","author":"Salzer","year":"2014","journal-title":"J Dermatol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00018-003-2186-9","article-title":"Cathelicidins - a family of multifunctional antimicrobial peptides","volume":"60","author":"Bals","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/ijms17091562","article-title":"Rosacea: molecular mechanisms and Management of a Chronic Cutaneous Inflammatory Condition","volume":"17","author":"Woo","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jid.2022.10.020","article-title":"Cathelicidin LL-37 activates human keratinocyte autophagy through the P2X\u2087, mechanistic target of rapamycin, and MAPK pathways","volume":"143","author":"Ikutama","year":"2023","journal-title":"J Investig Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1092473","DOI":"10.3389\/fphar.2023.1092473","article-title":"EGCG identified as an autophagy inducer for rosacea therapy","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/15548627.2020.1725381","article-title":"Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation","volume":"17","author":"Wang","year":"2021","journal-title":"Autophagy"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e13560","DOI":"10.15252\/emmm.202013560","article-title":"A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Deng","year":"2021","journal-title":"EMBO Mol Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jid.2016.10.046","article-title":"TRPV4 mediates mast cell activation in cathelicidin-induced Rosacea inflammation","volume":"137","author":"Mascarenhas","year":"2017","journal-title":"J Investig Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/exd.13143","article-title":"Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics","volume":"26","author":"Holmes","year":"2017","journal-title":"Exp Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s13238-017-0395-5","article-title":"TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization","volume":"8","author":"Gouin","year":"2017","journal-title":"Protein Cell"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/jid.2011.424","article-title":"Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea","volume":"132","author":"Sulk","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0190-9622(90)70264-I","article-title":"The mast cell in health and disease","volume":"23","author":"Rothe","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00403-007-0816-z","article-title":"A study of the pathogenesis of Rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process","volume":"300","author":"Aroni","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/all.12083","article-title":"Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation","volume":"68","author":"Krause","year":"2013","journal-title":"Allergy"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/0394632015600598","article-title":"Platelet activating factor in allergies","volume":"28","author":"Pa\u0142gan","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"880850","DOI":"10.3389\/fimmu.2022.880850","article-title":"UVB-induced microvesicle particle release and its effects on the cutaneous microenvironment","volume":"13","author":"Frommeyer","year":"2022","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fimmu.2012.00185","article-title":"TLR signaling in mast cells: common and unique features","volume":"3","author":"Sandig","year":"2012","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2018.00868","article-title":"Controlling mast cell activation and homeostasis: work influenced by bill Paul that continues today","volume":"9","author":"Caslin","year":"2018","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/jidsymp.2011.9","article-title":"Rosacea: the cytokine and chemokine network","volume":"15","author":"Gerber","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"879021","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 Inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","article-title":"The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis","volume":"10","author":"Franchi","year":"2009","journal-title":"Nat Immunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1074-7613(00)80209-5","article-title":"Caspase-1 activation of IL-1\u03b2 and IL-18 are essential for Shigella flexneri\u2013induced inflammation","volume":"12","author":"Sansonetti","year":"2000","journal-title":"Immunity"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases*","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/exd.12030","article-title":"Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation","volume":"21","author":"Casas","year":"2012","journal-title":"Exp Dermatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1111\/jocd.14816","article-title":"Rosacea management: a comprehensive review","volume":"21","author":"Sharma","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"ref54","first-page":"20","article-title":"Comprehensive medical management of rosacea: an interim study report and literature review","volume":"1","author":"Del Rosso","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1590\/abd1806-4841.20163541","article-title":"Skin barrier in rosacea","volume":"91","author":"Addor","year":"2016","journal-title":"An Bras Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/ics.12721","article-title":"Role of pH in skin cleansing","volume":"43","author":"Hawkins","year":"2021","journal-title":"Int J Cosmet Sci"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1111\/jocd.14020","article-title":"Impact of ultraviolet radiation and exposome on rosacea: key role of photoprotection in optimizing treatment","volume":"20","author":"Morgado-Carrasco","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"ref58","first-page":"31","article-title":"A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for Rosacea patients","volume":"4","author":"Levin","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jocd.12889","article-title":"A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin","volume":"18","author":"Baldwin","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","article-title":"Standard management options for rosacea: the 2019 update by the National Rosacea Society expert committee","volume":"82","author":"Thiboutot","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.12688\/f1000research.16537.1","article-title":"Recent advances in understanding and managing rosacea","volume":"7","author":"Buddenkotte","year":"2018","journal-title":"F1000Research"},{"key":"ref62","first-page":"14","article-title":"Nonantibiotic properties of Tetracyclines in Rosacea and their clinical implications","volume":"14","author":"Del Rosso","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/CCID.S194074","article-title":"Conventional and novel treatment modalities in Rosacea","volume":"13","author":"Engin","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref64","first-page":"S17","article-title":"Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS)","volume":"13","author":"Del Rosso","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref65","first-page":"s101","article-title":"Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid","volume":"13","author":"Del Rosso","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaad.2013.05.019","article-title":"Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel","volume":"69","author":"Coda","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jocd.14098","article-title":"A novel azelaic acid formulation for the topical treatment of inflammatory rosacea: a multicentre, prospective clinical trial","volume":"20","author":"Dall'Oglio","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"ref68","first-page":"299","article-title":"Treatment of papulopustular rosacea with sodium sulfacetamide 10%\/sulfur 5% emollient foam","volume":"8","author":"Trumbore","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"ref69","first-page":"485","article-title":"The role of skin care and maintaining proper barrier function in the Managment of Rosacea","volume":"20","author":"Del Rosso","year":"2007","journal-title":"Cosmet Dermatol"},{"key":"ref70","first-page":"94","article-title":"Topical metronidazole: a new therapy for rosacea","volume":"9","author":"Schmadel","year":"1990","journal-title":"Clin Pharm"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00128071-200001030-00007","article-title":"Topical Metronidazole","volume":"1","author":"McClellan","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"ref72","first-page":"36","article-title":"Enhancing topical pharmacotherapy for acne and Rosacea: vehicle choices and outcomes","volume":"15","author":"Green","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref73","first-page":"16","article-title":"Minocycline extended-release comparison with doxycycline for the treatment of Rosacea: a randomized, head-to-head, clinical trial","volume":"14","author":"Tsianakas","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref74","first-page":"461","article-title":"Treatment options for acne rosacea","volume":"80","author":"Goldgar","year":"2009","journal-title":"Am Fam Physician"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1169916","DOI":"10.3389\/fphar.2023.1169916","article-title":"Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref76","first-page":"54","article-title":"Use of oral isotretinoin in the management of rosacea","volume":"4","author":"Park","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jid.2016.03.003","article-title":"Low-dose isotretinoin: an option for difficult-to-treat Papulopustular Rosacea","volume":"136","author":"Van Zuuren","year":"2016","journal-title":"J Investig Dermatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/jid.2012.111","article-title":"Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients","volume":"132","author":"Dispenza","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e14520","DOI":"10.1111\/dth.14520","article-title":"Facial flushing and erythema of rosacea improved by carvedilol","volume":"33","author":"Seo","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective \u03b2-adrenergic blocker","volume":"67","author":"Hsu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"609615","DOI":"10.3389\/fimmu.2021.609615","article-title":"A novel mechanism of carvedilol efficacy for Rosacea treatment: toll-like receptor 2 inhibition in macrophages","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fmed.2019.00324","article-title":"The Theranostics role of mast cells in the pathophysiology of Rosacea","volume":"6","author":"Wang","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s13555-021-00597-7","article-title":"Mast cell stabilizers in the treatment of Rosacea: a review of existing and emerging therapies","volume":"11","author":"Marchitto","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3889\/oamjms.2019.784","article-title":"Botulin toxin use in Rosacea and facial Flushing treatment","volume":"7","author":"Scala","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdermsci.2018.12.004","article-title":"Botulinum toxin blocks mast cells and prevents rosacea like inflammation","volume":"93","author":"Choi","year":"2019","journal-title":"J Dermatol Sci"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"e10874","DOI":"10.1016\/j.heliyon.2022.e10874","article-title":"Current research and clinical trends in rosacea pathogenesis","volume":"8","author":"Hu","year":"2022","journal-title":"Heliyon"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"384","DOI":"10.36849\/JDD.5861","article-title":"Evidence of barrier deficiency in Rosacea and the importance of integrating OTC skincare products into treatment regimens","volume":"20","author":"Baldwin","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"674871","DOI":"10.3389\/fimmu.2021.674871","article-title":"Keratinocyte-immune cell crosstalk in a STAT1-mediated pathway: novel insights into Rosacea pathogenesis","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Investig Dermatol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"e15848","DOI":"10.1111\/dth.15848","article-title":"Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case series","volume":"35","author":"Sun","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5021\/ad.2012.24.2.126","article-title":"Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease","volume":"24","author":"Reinholz","year":"2012","journal-title":"Ann Dermatol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcell.2021.751785","article-title":"mTORC1-mediated angiogenesis is required for the development of Rosacea","volume":"9","author":"Peng","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2340\/00015555-2300","article-title":"Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review","volume":"96","author":"Nadal","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1080\/15548627.2015.1106668","article-title":"MTOR, PIK3C3, and autophagy: signaling the beginning from the end","volume":"11","author":"Munson","year":"2015","journal-title":"Autophagy"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.3390\/ijms22083968","article-title":"Rapamycin alleviates 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced aggravated dermatitis in mice with Imiquimod-induced psoriasis-like dermatitis by inducing autophagy","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref96","first-page":"267","volume-title":"Celastrol and its role in controlling chronic diseases","author":"Venkatesha","year":"2016"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"113292","DOI":"10.1016\/j.biopha.2022.113292","article-title":"Celastrol inhibits LL37-induced rosacea by inhibiting ca(2+)\/CaMKII-mTOR-NF-kappaB activation","volume":"153","author":"Zeng","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"109011","DOI":"10.1016\/j.biopha.2019.109011","article-title":"Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-kappaB activation in keratinocytes","volume":"116","author":"Chen","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.2147\/DDDT.S393122","article-title":"Thalidomide attenuates skin lesions and inflammation in Rosacea-like mice induced by Long-term exposure of LL-37","volume":"16","author":"Kang","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"110057","DOI":"10.1016\/j.intimp.2023.110057","article-title":"Supramolecular salicylic acid ameliorates rosacea-like eruptions by suppressing NLRP3-mediated inflammasome activation in mice","volume":"118","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/exd.13934","article-title":"Salicylic acid treats acne vulgaris by suppressing AMPK\/SREBP1 pathway in sebocytes","volume":"28","author":"Lu","year":"2019","journal-title":"Exp Dermatol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting toll-like receptors: emerging therapeutics?","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/187152807783334300","article-title":"TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders","volume":"6","author":"Sun","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1124\/jpet.102.044487","article-title":"Inhibition of endotoxin response by e5564, a novel toll-like receptor 4-directed endotoxin antagonist","volume":"304","author":"Mullarkey","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2337363","article-title":"NPT1220-312, a TLR2\/TLR9 small molecule antagonist, inhibits pro-inflammatory signaling, cytokine release, and NLRP3 Inflammasome activation","volume":"2022","author":"Habas","year":"2022","journal-title":"Int J Inflamm"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaad.2014.08.027","article-title":"Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors","volume":"72","author":"Two","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.det.2017.11.001","article-title":"Rosacea pathogenesis","volume":"36","author":"Ahn","year":"2018","journal-title":"Dermatol Clin"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/jid.2014.222","article-title":"Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea","volume":"134","author":"Muto","year":"2014","journal-title":"J Invest Dermatol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"106178","DOI":"10.1016\/j.intimp.2019.106178","article-title":"Hydroxychloroquine is a novel therapeutic approach for rosacea","volume":"79","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaad.2020.05.050","article-title":"Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double-blind, double-dummy, pilot study","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"109181","DOI":"10.1016\/j.biopha.2019.109181","article-title":"Artemisinin, a potential option to inhibit inflammation and angiogenesis in rosacea","volume":"117","author":"Yuan","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaci.2021.03.049","article-title":"Multifaceted MRGPRX2: new insight into the role of mast cells in health and disease","volume":"148","author":"Roy","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.jid.2022.05.005","article-title":"Role of MrgprB2 in Rosacea-like inflammation in mice: modulation by betaarrestin2","volume":"142","author":"Roy","year":"2022","journal-title":"J Invest Dermatol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fphar.2019.00124","article-title":"Therapeutic potential of targeting \u00df-Arrestin","volume":"10","author":"Bond","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2174\/1570161112666141014145440","article-title":"Cellular membrane microparticles: potential targets of combinational therapy for vascular disease","volume":"13","author":"Xiao","year":"2015","journal-title":"Curr Vasc Pharmacol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/php.12703","article-title":"UVB-generated microvesicle particles: a novel pathway by which a skin-specific stimulus could exert systemic effects","volume":"93","author":"Fahy","year":"2017","journal-title":"Photochem Photobiol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/php.12577","article-title":"UVB generates microvesicle particle release in part due to platelet-activating factor signaling","volume":"92","author":"Bihl","year":"2016","journal-title":"Photochem Photobiol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"e144963","DOI":"10.1172\/JCI144963","article-title":"Keratinocyte-derived microvesicle particles mediate ultraviolet B radiation-induced systemic immunosuppression","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/jm070524a","article-title":"Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model","volume":"51","author":"Kornhuber","year":"2008","journal-title":"J Med Chem"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jaad.2023.01.044","article-title":"Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the prospective Rosacea refractory erythema randomized clinical trial","volume":"88","author":"Wang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fphys.2014.00331","article-title":"Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons","volume":"5","author":"Beckmann","year":"2014","journal-title":"Front Physiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1292722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:29:02Z","timestamp":1702423742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1292722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":121,"alternative-id":["10.3389\/fmed.2023.1292722"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1292722","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"article-number":"1292722"}}